REGN · Healthcare

REGENERON PHARMACEUTICALS, INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…
Capital Return ProgramImportance 10 · Surprise 6
Regeneron confirmed its quarterly dividend following the release of Q2 and first-half 2026 results. The company also provided an update on share repurchases, although the digest did not specify the repurchase amount or…

Intellia Gene-Editing PartnershipImportance 34 · Surprise 42
Intellia reported that clinical holds on its Regeneron-partnered nexiguran ziclumeran, or nex-z, programs were lifted. Enrollment in key ATTR studies is progressing, with completion of MAGNITUDE-2 enrollment expected…
Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…

CytomX Collaboration ExpansionImportance 34 · Surprise 42
CytomX reported that its collaboration with Regeneron was expanded in connection with its Varseta-M cancer program. The agreement generated a $37.0 million payment in July 2026 and provides for potential milestone…
Intellia Gene-Editing PartnershipImportance 34 · Surprise 42
Intellia reported that clinical holds on its Regeneron-partnered nexiguran ziclumeran, or nex-z, programs were lifted. Enrollment in key ATTR studies is progressing, with completion of MAGNITUDE-2 enrollment expected…

Competition and Market ShareImportance 34 · Surprise 42
Regeneron faces new biosimilar competition for Eylea, one of its key ophthalmology products. The competitive pressure is relevant to both standard-dose Eylea and the company’s broader ophthalmology franchise, which…
Securities Fraud LitigationImportance 34 · Surprise 42
Multiple law firms reported that securities class actions have been filed against Regeneron and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The allegations…
Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…

Securities Fraud LitigationImportance 34 · Surprise 42
Multiple law firms reported that securities class actions have been filed against Regeneron and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The allegations…